CAP Accreditation

Downloaded LogoPGXL’s expanded lab has been accredited by the College of American Pathologists (CAP) after an exacting period of preparation and inspection. PGXL is now both CLIA and CAP certified, testament to our lab staff’s meticulous dedication.

by Tom Johnson

PGXL Software Cleared for Clinical Trials

PeRMIT Warf Logo 541PGXL’s PerMIT software has received regulatory clearance for a clinical trial involving up to 720 patients.

PerMIT:Warfarin is a decision support software that provides a graphic display of historical and projected aspects of warfarin therapy. It analyzes genetic and other data to provide information physicians can apply in the dosing and monitoring of the most commonly prescribed anticoagulant.

An earlier, small study of PerMIT indicated that use of the software got patients to therapeutic stability in a shorter time than those treated without the software. This new clinical trial is designed to determine whether the software reduces the risk of adverse drug reactions in real-world therapy.

To read more about the PerMIT:Warfarin clinical trial, CLICK HERE.

by Tom Johnson

Entrepreneur of the Year

Entrepreneur of hte YearErnst & Young recognizes PGXL’s President, Dr. Roland Valdes Jr., as Entrepreneur of the Year. PGXL began as a scientific insight in Dr. Valdes’ lab at the University of Louisville — that genetic information could be used to predict the efficacy of different treatments for specific patients. PGXL has grown to more than 50 employees with a commitment to bringing the benefits of Personalized Medicine to everyone.

by Tom Johnson

PGXL Opens Anatomic Pathology Lab

The first commercial samples are going through our new AP lab today. It’s going to be small volume for a little while, as we make sure our systems and processes are right. But it’s still very exciting.

AP Lab Samples 600

by Tom Johnson

PGXL Begins Analysis of Exosomes and Microparticles

PGXL Technologies has formed a strategic partnership with NX PharmaGen (NXPG) to support the identification of biomarkers using their NeXosome™ microparticle enrichment technology. Exosomes and microparticles, which are found in bodily fluids, aid diagnosis and treatment of cancer, immunological disorders, preterm birth, diseases of the central nervous system and other medical conditions.

Under this partnership, NXPG and PGXL Technologies are forming the PGXL NeXosomeTM Center of Excellence, whose mission is to provide access to advanced technologies that isolate and analyze exosomes and  particles in bodily fluids. This center is the first of its kind to offer access to the NeXosome enrichment platform and downstream  assay development in a CLIA setting, with a mission to accelerate new discoveries into clinically useful applications.

To see the detailed press release on the agreement, CLICK HERE.

To read the technical details of the NeXosome techonlogy, CLICK HERE.

To visit PharmaGen’s website, CLICK HERE.

by Tom Johnson

PGXL Technologies Receives Grant through KY SBIR-STTR Match Program

PGXL Technologies has been awarded $149,910 through the Kentucky Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Matching Funds program. The Kentucky SBIR-STTR funds will be used to match a federal phase NIH/NCI grant contract PGXL Technologies received in September 2013 to fund development of a platform for isolation and analysis of circulating tumor cells (CTC) in breast cancer.

To read the entire press release, please click here.

by Tom Johnson

PGXL is now licensed in California

PGXL is pleased to announce that we are now licensed to test in the state of California and are now selling in all 50 states.

To view the press release, please click here.

To see our test menu, please click here.

by Tom Johnson

GLI’s Fast Dozen of 2014

PGXL Laboratories was recently named to the Fast Dozen Showcase as one of the top fastest growing companies headquartered in the Metro Louisville region.

To view the press release, please click here.

by Tom Johnson

Next Gen Sequencer Arrives

SeuencerThe lab is all aflutter.

by Tom_Johnson

Histology Webinar

NSH_logoJoelle Weaver, PGXL histologist, will give a webinar December 17, 2014, to the National Society for Histotechnology,

Weaver will explain her personal methodology for validating and correlating qualitative-predictive assays, particularly HER2, an important breast cancer biomarker.

Go here for information about the webinar.

by Tom_Johnson